Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Omega Therapeutics, Inc. (OMGA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.00-0.23 (-1.03%)
At close: 4:00PM EDT
22.00 0.00 (0.00%)
After hours: 04:41PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close22.23
Open22.14
Bid21.51 x 900
Ask22.07 x 800
Day's Range21.83 - 22.62
52 Week Range15.50 - 24.29
Volume32,801
Avg. Volume124,778
Market Cap1.051B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.06
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OMGA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Omega Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/04/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • PR Newswire

    Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine

    Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammat

  • PR Newswire

    Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

    Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Mahesh Karande, President and Chief Executive Officer, will participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET.

  • PR Newswire

    Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives

    Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the second quarter ended June 30, 2021.

Advertisement
Advertisement